Proactive Investors - Run By Investors For Investors

Opthea developing novel therapies for treating eye disease

Megan Baldwin, chief executive officer of Opthea Ltd (ASX:OPT), spoke to Proactive Investors at the ASX Small and Mid-Cap Conference in Sydney.

Opthea is a Victorian company focused on commercialising eye therapeutics and plans to enrol and dose patients in two phase 2-stage clinical trials in the next 12 months. The healthcare company also plans to finish recruiting and dosing patients in its 351-patient phase 1b/2a clinical trial in diabetic macular edema in the next year.

 
Meet Metro Mining Ltd at our event, Melbourne , 10 April 2019. Register here »
View full OPT profile View Profile

Opthea Ltd Timeline

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use